LEXICON PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$32.42 million for the 3-month period ending 2016-12-31, per its 10-K filed 2017-03-06.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2017-03-06
- LEXICON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-12-31 was -$32.42M, a 137.37% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$36.02M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-06-30 was -$38.11M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-03-31 was -$34.88M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$32.42M 10-K · filed 2017-03-06 | -$68.43M derived: sum of 2 quarters · filed 2017-03-06 | -$106.55M derived: sum of 3 quarters · filed 2017-03-06 | -$141.43M derived: sum of 4 quarters · filed 2017-03-06 |
| 2016-09-30 | -$36.02M 10-K · filed 2017-03-06 | -$74.13M derived: sum of 2 quarters · filed 2017-03-06 | -$109.01M derived: sum of 3 quarters · filed 2017-03-06 | -$22.26M derived: sum of 4 quarters · filed 2017-03-06 |
| 2016-06-30 | -$38.11M 10-K · filed 2017-03-06 | -$73.00M derived: sum of 2 quarters · filed 2017-03-06 | $13.76M derived: sum of 3 quarters · filed 2017-03-06 | -$21.53M derived: sum of 4 quarters · filed 2017-03-06 |
| 2016-03-31 | -$34.88M 10-K · filed 2017-03-06 | $51.87M derived: sum of 2 quarters · filed 2017-03-06 | $16.59M derived: sum of 3 quarters · filed 2017-03-06 | -$9.49M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-12-31 | $86.75M 10-K · filed 2017-03-06 | $51.47M derived: sum of 2 quarters · filed 2017-03-06 | $25.39M derived: sum of 3 quarters · filed 2017-03-06 | -$2.68M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-09-30 | -$35.28M 10-K · filed 2017-03-06 | -$61.36M derived: sum of 2 quarters · filed 2017-03-06 | -$89.43M derived: sum of 3 quarters · filed 2017-03-06 | -$92.36M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | -$26.07M 10-K · filed 2017-03-06 | -$54.15M derived: sum of 2 quarters · filed 2017-03-06 | -$57.08M derived: sum of 3 quarters · filed 2017-03-06 | -$97.58M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | -$28.08M 10-K · filed 2017-03-06 | -$31.01M derived: sum of 2 quarters · filed 2017-03-06 | -$71.51M derived: sum of 3 quarters · filed 2017-03-06 | -$97.53M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | -$2.93M 10-K · filed 2016-03-11 | -$43.43M derived: sum of 2 quarters · filed 2016-03-11 | -$69.46M derived: sum of 3 quarters · filed 2016-03-11 | -$100.29M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-09-30 | -$40.50M 10-K · filed 2016-03-11 | -$66.53M derived: sum of 2 quarters · filed 2016-03-11 | -$97.36M derived: sum of 3 quarters · filed 2016-03-11 | |
| 2014-06-30 | -$26.03M 10-K · filed 2016-03-11 | -$56.86M derived: sum of 2 quarters · filed 2016-03-11 | ||
| 2014-03-31 | -$30.84M 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |